A B S T R A C T Metabolic clearance rates (MCR) and production rates (PR) of prolactin (PRL) have been determined by the constant infusion to equilibrium technique in 11 normal subjects, 6 patients with hyperthyroidism, 4 patients with hypothyroidism, and 9 patients with hyperprolactinemia. PRL MCR was also determined in four patients during dopamine infusion. Mean PRL MCR was 46±1 ml/min per m2 in women and 44±3 ml/min per m2 in men, and was significantly correlated with body mass (r = 0.84, P < 0.001). In contrast with controls, PRL MCR was higher in hyperthyroidism (MCR = 52±8 ml/min per mi2, P < 0.05), was slightly lower in hypothyroidism (MCR = 38+10 ml/min per m2, P = NS), and was significantly correlated with serum thyroxine (r = 0.46, P < 0.02). PRL MCR was lower than controls in hyperprolactinemia (MCR = 40+5 mllmin per i2, P <0.01) and was inversely correlated with serum PRL (r = -0.72, P < 0.001). PRL MCR was not significantly changed by dopamine infusion.
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Mean PRL PR for women and men was 211±74 and 187±44 ,ug/d per m2, respectively (P = NS). In hyperthyroidism the PRL PR was elevated (PR = 335±68 ,ug/d per m2, P < 0.02), but in hypothyroidism the increase (PR = 233±159 ,tg/d per m2) was not significant. In hyperprolactinemia the PRL PR was extremely high (PR = 31,000±29,000 ,ig/d per m2).
Dopamine infusion decreased PRL PR from 270 to 66
,ug/d per m2 indicating that its effect was on pituitary PRL secretion and not PRL metabolism.
To evaluate possible circulating PRL heterogeneity that might arise during infusion, gel filtration of infusate and serum obtained during the MCR procedure was performed. Labeled monomeric PRL (peak III, Kav (partition coefficient) = 0.4) was partially INTRODUCTION The circulating concentration of a hormone is de- termined not only by the production rate of that hormone (PR),' but also by its metabolic clearance rate (MCR). Knowledge of hormonal MCR has become necessary for a complete understanding of physiologic and pathologic changes in peripheral hormone concentrations. Since 1963, the constant infusion to equilibrium technique of Tait (1) has been used to measure the MCR of both steroids and polypeptide hormones. The advantage ofthis method over previous single-injection techniques is that knowledge of the complex disappearance curve of an infused hormone is not necessary for MCR calculations. The only prerequisites are that equilibrium be reached during the infusion and that labeled and unlabeled hormones be metabolized identically (1) .
The MCR of growth hormone (GH), luteinizing hormone, follicle-stimulating hormone, thyrotropinstimulating hormone (TSH), and the subunits of TSH have been determined by this method (2) (3) (4) (5) (6) (7) (8) (9) . Although the MCR of prolactini (PRL) has been imeasured in both the rat (10) ani-d sheep (11) in this mannier, comparable data in humanis have not been reported. The following study was designed to determine the MCR of PRL in humans, and, Usinlg amllbient hormone levels, to calculate the daily produiction rate of PRL in normal subjects, and in variouis patthologic states (hyperthyroidism, hypothyroidism, and hyperprolactinemia). In addition, the effect of dopacmine on the MCR and PR of PRL was investigated b)ecause dopaminie causes a substantial reduction in circulating PRL levels (12) . To validate these methods, gel filtration and immunologic characterization of radioiodinated PRL were performned to assess the impact that hormonie heterogeneity and metabolismii might have on MICR calculations. METHODS lodination of human PRL. Highly purified huimian PRL was supplied by the National Pituitary Ageincy (VIS-3, VLS-4) and by Dr. Albert Parlow (AFP-1582-C). The horinone was reconstituted in 0.01 M NH4HCO3 buffer, pH 8.2, and stored at -70°C. lodination with 1251 to a specific activity of 50-100 ,uCi/,g was carried out using a modified chloramine T method or the lactoperoxidase method (13 At equilibriumn, labeled PRL was iminunoprecipitated fioni 0.8 ml of sera or infusate by the double antibody techni(lue using a final rabbit anti-PRI antibody titer of 1:100. The imnmunoprecipitability of infusate ranged froml 45 to 83% depending on the hormonie used for iodination, the specific activity, and the age of the iodinated PRL.
Determinitatiotn ofPRL MICR. The nmean countts per minute per milliliter froin at least three points during the final hour of infusion were averaged. The infusion rate in counts per minute was calculated as the product of the infusioni rate of the pumip in milliliters per minute and the immunoprecil)itable cotinits I)er iminutte per milliliter of "'5I-PRL in tIme infusate.
MCR (ml/min)
Imniunoprecipitable 1251-PRL in infusate (cpin/miil) x infusioii rate (iml/imiin) Serum concentration ofimmunoprecipitable 1251-PRL at equilibrium (cpin/ml) Serum PRL concentrations. Serum PRL was determined by a homologous radioimmunoassay using amniotic fluid PRL standards calibrated against MRC Research Standard A 71/222 (Medical Research Council of Canada). 1 ng of our PRL standard is equivalent to 16 ,U of the MRC standard. A double antibody system was used to separate bound from free hormone. 50-,ul serum samples were incubated at 4°C with 100 Al rabbit anti-PRL antibody (1:10,000 final concentration) and 750 1.d 0.05 M phosphate buffer containing 0.1% bovine serum albumin. After 48 h, 100 pg 125I1 PRL tracer were added and, after 24 h at 4°C, samples were precipitated with goat anti-rabbit gamma globulin. The sensitivity of the assay is 1 ng/ml, with interassay variation of 15% and intraassay variation of 8%. In this assay, the mean normal serum PRL concentration for females is 4.8±2.2 ng/ml (range, 0 to 12 ng/ml), and is 3.7±2.7 ng/ml (range, 0 to 10 ng/ml) for males. To eliminate interassay variation, all basal PRL determinations were performed in the same assay.
Determination of PRl, PR. The PRL PR was calculated as the product of the endogenous serum PRL concentration and the MCR. Serum PRL levels were drawn between 8:00 and 10:00 a.m. The PRL PR (micrograrns/day) = NICR (milliliters/minlute) x [PRL] (nanograrns/milliliter) x 1,440 min/d.
Patientts. Control volunteer subjects and patients with various diseases were studied in the Clinical Research Center of the Massachusetts General Hospital, Boston, 'Mass., after informed consent was obtained. All subjects except those with thyroid disease were pretreated with 270 mg KI before the '25I-PRL infusioii, to block uptake of free 1251 by the thyroid. For testing with thyrotropin-releasing hormone (TRH), 200 jig TRH (Protirelin, Abbott Laboratories, North Chicago, Ill.) was injected as a bolus, and blood was sampled at 0, 10, 20, 30, 45, 60, and 120 min (14) .
Controls. 11 healthy subjects (5 men aged 23-65 yr and 6 premnenopausal women aged 24-53 yr, in the follicular phase of the nmenstrual cycle) were studied. All had normnal pituitary, thyroid, renal, and liver function. One subject was studied twice to test the precision of the procedure, as well as to test the possibility that PRL labeled by the chloramine T method might be cleared differently from that labeled by the lactoperoxidase technique. One man and two womnen had blood sampled hourly through an indwellinig catheter for 24 h to characterize a daily secretory profile for PRL.
Thyroid disease. Six patients with Graves' disease (five women and one man, mean age 33 yr) were studied before therapy. The patients were hyperthyroid by clinical criteria, and all had elevations of serum thyroxine (T4) aind triiodothyronine (T3), and undetectable serum TSH levels. Four patients with primary hypothyroidism were studied (three women and one man, mean age 52 yr). One patient had Hashimoto's thyroiditis, two patients had had thyroid ablation 5 and 10 yr earlier with 131I, and one patient had propylthiouracil-induced hypothyroidism of at least 3-mo duration. All had markedly decreased serum T, and T3 with concomitant elevations of serum TSH levels. Serum T4, T3, and TSH were measured by radioimmunoassay (14, 15) .
Hyperprolactinemia. Eight patients (six women and two men, mean age 30 yr) with PRL-secreting pituitary adenomas, and one woman with idiopathic hyperprolactinemia were studied. Seven patients were euthyroid, and two patients (patients 27 and 29) had secondary hypothyroidism. Two patients with tumors were studied both before and after transsphenoidal hypophysectomy, and the remaining six were studied before proton beam pituitary irradiation. Dopamine infusion. Four subjects (three normal and one with idiopathic hyperprolactinemia) underwent a standard MCR determination. 1 wk later, they had the same procedure performed together with a simultaneous dopamine infusion. Dopamine, 200 mg (Intropin, Arnar-Stone Laboratories, Mount Prospect, Ill.), was mixed in 500 ml 5% dextrose in water and infused at the rate of 4 ,Ag/kg per min. Blood pressure and pulse were monitored every 30 min and did not change significantly over 2 h. After 2 h of infusion, the PRL MCR was determined by the previously described methods, during which time the dopamine infusion was continued.
Gel chromatography of 1251-PRL. To investigate the heterogeneity of labeled PRL, gel chromatography of infusate and sera was performed. Infusate (20, 000 cpm) or 4 ml of serum obtained at 5 and 180 min of the constant infusion were chromatographed on a 1.5 x 90-cm Sephadex G-100 column at 4°C. All samples were chromatographed within 24 h of the infusion. 1-ml fractions were collected and counted, and radioactive peaks were immunoprecipitated with excess anti-PRL antisera (1:100).
Polyacrylamide gel electrophoresis ofPRL. To investigate the molecular nature of the heterogeneous species of PRL, each iodination peak (Fig. 5A ) was subjected to denaturing polyacrylamide gel electrophoresis (PAGE) . Approximately 100,000 cpm of peaks I, II, and III were placed in 2% sodium dodecyl sulfate (SDS), 0.05 M Tris buffer, pH 6.8, with or without 1% f3mercaptoethanol. Samples were applied to 0.6 x 9 cm SDS containing 7.5% polyacrylamide-0.2% bisacrylamide (Eastman Organic Chemicals Div., Eastman Kodak Co., Rochester, N. Y.) gels, and electrophoresed with a current of 2 mA/gel in a continuous 0.05 M Tris-0.4 M glycine-0.1% SDS buffer system, pH 8.4. Gels containing 1251_PRL were sliced and counted. Slices were incubated in 0.05 M P04, 0.1% SDS solution for 2 h at 37°C, and the eluted counts were immunoprecipitated as described above.
The concentrations of SDS or f3mercaptoethanol used in these studies did not affect immunoactivity of labeled PRL.
Statistics. The significance of differences was analyzed by Student's t test. Linear regression analysis was performed by the method of least squares.
RESULTS
Labeled and unlabeled PRL disappearance curves. The initial rate of disappearance (distribution phase) of 125I-PRL and unlabeled PRL was similar in the dog (P for slopes = 0.4, NS). These data validated the use of labeled PRL in subsequent studies.
PRL MCR and PR in normal subjects. A typical example of the MCR procedure is shown in Fig. 1 . Equilibrium was reached by 90-120 min, after which the variation of immunoprecipitable counts was no >+10%. Women had a mean MCR of 79±+10 ml/min (46+1 ml/min per M2) and men had a mean MCR of 78±+11 ml/min (44+3 ml/min per m2) (Table I ). Because there was a significant positive correlation (r = 0.84, P <0.001, Fig. 2 ) between the MCR and body surface area, all results have been corrected for surface area. One subject (subject 6) had a MCR measured twice, with the repeat value (45 ml/min per m2) being very similar to the original value (48 ml/min per m2). It was also demonstrated in this subject that there was no difference in the MCR of PRL iodinated with chloramine T vs. that iodinated with lactoperoxidase (13 There was no significant difference between these two groups (P 0.7).
PRL MCR and PR in thyroid disease. The mean PRL MCR in hyperthyroid patients was 52±8 ml/min per m2, which was significantly higher than the control value of 46±4 ml/min per M2 (P < 0.05) ( Table  II) . The mean PRL MCR in the hypothyroid patients was decreased (38+10 ml/min per m2) but was not significantly lower than control or hyperthyroid subjects (Table II) . There was a small but significant direct correlation between PRL MCR and serum T4 levels (r = 0.46, 0.01 < P < 0.02, Fig. 3 ), but no such relationship was observed for serum T3 levels (data not shown). Mean basal PRL for the hyperthyroid patients was 4.5+ 1.1 ng/ml, which was significantly higher than the normal control value of3.0+ 1.1 ng/ml (0.01 < P < 0.02). In addition the mean PRL PR for this group was 335±68 ,ug/d per m2, which was significantly greater than the normal value of 200±63 gg/d per m2 (0.01 < P < 0.02). In the hypothyroid subjects, mean basal PRL was 4.1±2.1 ng/ml, and the mean PRL PR was 233+159 lSg/d per m2. Both values were slightly higher than normal, but the differences were not significant.
The mean peak PRL after TRH in hyperthyroid SURFACE AREA (m2 FIGURE 2 Positive correlation of PRL MCR with body surface area in normal subjects (r = 0.84, P < 0.001). subjects was 6.9+2.8 ng/ml, which was significantly lower than the control value of 19.8±+10 ng/ml (P < 0.01). Hypothyroid subjects had a mean peak PRL after TRH of 43 .2+16 ng/ml, which was significantly higher than controls (0.01 < P < 0.02).
PRL MCR and PR in hyperprolactinemic patients. Eight patients with a PRL-secreting pituitary adenoma and one patient with idiopathic hyperprolactinemia were studied (Table II) . The mean PRL MCR of 40+5 ml/min per m2 was significantly lower than the mean value obtained for normal controls (0.02 < P < 0.05). There was a highly significant inverse correlation between the logarithm of the serum PRL and the PRL MCR (r = -0.72, P < 0.001, Fig. 4 Gel chromatography of labeled PRL. Gel filtration studies were performed because of the possibility that PRL was altered after infusion, forming iodinated species with molecular weights different from native or peak III PRL, yet that were immunoprecipitable with anti-PRL antisera. These species would then be included in the MCR calculations as "immunoprecipitable 125I," and yet would not represent native PRL. These additional counts would, therefore, falsely lower the true PRL MCR for the reason that these counts appear in the denominator of the MCR equation (MCR = infusion rate . circulating concentration). Fig. 5A shows the elution profile of '25I-PRL after iodination with lactoperoxidase (13) . Three protein peaks (I, II, and III) were evident. Using excess anti-PRL antisera (1:100), 20-30% of peak I, 0% of peak II, and 65-90% of peak III counts were immunoprecipitable. Peak III (native PRL), when rechromatographed after incubation in buffer at 37°C for 4 h, was not transformed into either peak I or peak II material (Fig. SB) . However, when this material was incubated in fresh serum at 37°C for 4 h, a small amount of peak I material was formed (Fig. 5C) . for all the subjects studied. The infusate, which was prepared with only peak III material, characteristically contained a small amount of void volume (peak I) material (s10%), but the major form (590%) was native (peak III) PRL (Fig. 6A ). 5 min after starting the infusion, the amount of peak I material had increased to 20-30% of that total radioactivity, and a small amount of peak II PRL had appeared (Fig. 6B) . After 180 min, a peak corresponding to 125I had appeared. At this time, the area under the curves of peak I, peak III, and 125I were approximately equal. In addition, 10-20% of the radioactivity was peak II material (Fig. 6C ). There was no apparent difference in elution pattern between those samples chromatographed at 4°C and at room temperature. After gel chromatography of infusate and serum, the eluted peaks were immunoprecipitated with the following results (expressed as percent total counts bound): peak I = 10-30%; peak II = 0%; peak III = 65-90%; and 1251 = 0%. Thus, the peaks of radioactivity that developed over time in the serum (Fig. 6C) (Fig. 5A) . Because the amount of radioactivity in serum was too low to be analyzed further, peaks I, II, and III from radioiodination were studied by SDS-PAGE. For these studies, it was assumed, but not proven, that peaks I, II, and III that arose during the infusion were qualitatively similar to peaks obtained during iodination.
SDS-PAGE of labeled PRL (Fig. 7A -C) . After denaturing PAGE, >90% of labeled peak I was converted to peak III (Fig. 7B ). There was no difference in the pattern when the sample was incubated in 1%
,3-mercaptoethanol. Before SDS-PAGE, peak I counts were 30% immunoprecipitable, but counts eluted from gel slices after SDS-PAGE (i.e., "peak III"), were 72% immunoprecipitable, similar to the immunoprecipitability of native peak III seen in Fig. 7A (2, 8, 9) . The severity and duration of the underlying thyroid disease are important, as illustrated by the significant correlation between serum T4 levels and PRL MCR (Fig. 3) . Davis and Borger (20) found a significant decrease in PRL MCR in the thyroidectomized lamb, and it is possible that our results would be comparable to theirs had we studied more patients and performed serial measurements in the same patient. Additionally, the hypothyroid group was older than the control group, a fact that could have contributed to the minor decrease in the MCR of these patients.
When compared with normal controls, the six hyperthyroid patients had a slight, but statistically significant, increase in mean PRL MCR, as well as a significantly higher mean basal PRL level. The calculated daily PRL PR was therefore higher than normal, in large part because of the higher basal PRL levels rather than the minor elevations in PRL MCR.
Our finding of increased PRL PR in hyperthyroidism is contrary to the commonly held notion that thyroid hormone administration results in decreased PRL secretion (in parallel to its effects on thyrotropin secretion). Although in vitro studies have shown that PRL secretion by pituitary cells is decreased after exposure to thyroid hormone (21) (22) (23) , doses of T4 in one study (21) were clearly supraphysiologic (1-10 AM), and other studies, which have used rat pituitary tumor cell lines (GH, and GH3), have employed T3, but not T4, for testing (22, 23) . In vivo, it has been shown that PRL levels do not change significantly after acute T4 administration (24) . However, in studies of PRL dynamics in chronic hyperthyroidism, normal or even slightly elevated basal PRL levels have been observed in many patients, although the data have not been emphasized or presented in detail (25) (26) (27) (28) . In three reports (25) (26) (27) , basal levels of PRL in hyperthyroid patients were equal to or higher than control, but the differences were not statistically significant. In a fourth study (28) , the mean basal PRL of 12+6.9 ng/ml was significantly higher than control values 4.3+4.9 ng/ml FIGURE 5 (A) Sephadex G-100 chromatograph (1.5 x 90-cm column) of a typical iodination of PRL by lactoperoxidase (13) . 1-ml fractions were collected and counted. V. (void volume) = 45 ml, Vt (total volume) = 140 ml. Three protein peaks are evident: peak I (void volume, Kav (partition coefficient) = 0), peak II (molecular weight 44,000, Kav = 0.2), and peak III (molecular weight _ 23,000, Kav = 0.4, native PRL). (B) Sephadex G-100 chromatograph of peak III (-20,000 cpm) PRL incubated in 0.05 M NaPO4 buffer, pH = 7.4, for 4 h at 37°C. There is no conversion of peak III to peak I. (C) Sephadex G-100 chromatograph of peak III (-20,000 cpm) PRL incubated in fresh human serum for 4 h at 37°C. There is some conversion ofpeak III to peak I, but there is no spontaneous deiodination.
(P < 0.05). In addition, elevation of basal serum PRL levels has been reported in hyperthyroid rats (29) .
Several recent studies have shown that hyperthyroid patients have elevated serum levels of total and free estradiol (30, 31) . Because estrogens are potent stimulators of PRL secretion in vivo (32) (16) , using an indirect method. This is consistent with reports of basal elevations of PRL in some, but not all, hypothyroid patients (34) . The duration and severity of the hypothyroid state is a likely explanation for the variability in the reported results (35) . Peak PRL after TRH was markedly elevated in our patients, in keeping with previously published data (25) .
The PRL MCR in hyperprolactinemic patients was significantly lower than control subjects. Saturation of PRL metabolic pathways by high hormone concentrations is one possible mechanism that would explain our findings. Although GH MCR in acromegalic patients was found to be no different from normal by two groups (2, 4), it was lower than controls in three patients studied by Thompson et al. (5) . A recent study in the rat demonstrated that in vivo binding of 125I1 GH to putative hepatic GH receptors was decreased by simultaneous administration of unlabeled GH (36) .
Dopamine and dopaminergic agonists have been demonstrated to inhibit PRL release from the pituitary gland, in vitro (37) and in vivo (38) . However, none of the in vivo studies has determined whether an increased PRL MCR could be partly responsible for the decline in serum PRL concentration, although this has been postulated by one group of workers (39). Certainly the augmented renal and splanchnic blood flow produced by dopamine (40) could increase the metabolism of many substances. Indeed, an increase in GH MCR has been noted in acromegalics treated with the dopaminergic agonist bromocriptine (41) . However, the data from our four subjects who underwent dopamine infusions did not support this hypothesis. The mean PRL MCR, before and during dopamine were essentially the same, whereas PRL serum concentrations and PRL PR declined dramatically, confirming the potent effect of dopamine as an inhibitor of pituitary PRL release.
PRL (42) , GH (43) , and placental lactogen (44) are known to occur in heterogeneous forms. For PRL, heterogeneity has been found in the circulation (44, 45) , in cerebrospinal fluid (46) , in amniotic fluid (47) , as well as in media from pituitary glands cultured in vitro (48) . These forms have gel elution profiles on Sephadex G-100 that are characteristic: (a) "BigProlactin Metabolic Clearance and Production Rates Big" (peak I) PRL, which elutes in the void volume and comprises -0-5% of total PRL immunoactivity, (b) "Big" (peak II, Kav = 0.2) PRL, which has a molecular weight of -44,000 and represents 10-20% of immunoactive PRL, and (c) native PRL (peak III, Kav = 0.4), which accounts for 80-90% of the total immunoactive PRL. The immunologic and biologic potencies of these three species are virtually identical by radioimmunoassay and radioreceptor assay (48) , although decreased receptor binding by peaks I and II has recently been reported (49) . Although there are differences in the relative amounts of the three PRL species under various clinical circumstances, the precise biological significance ofthe heterogeneity of PRL remains to be elucidated.
Three species of PRL are also observed when PRL is iodinated with chloramine T or lactoperoxidase (50, 51) . Although the three species have Kav that are identical to those seen with unlabeled PRL (50), they differ substantially from unlabeled peaks in their binding to anti-PRL antisera. Only 20-30% of peak I, essentially no peak II, and 70-90% of peak III counts are bound (50, 51) .
In the present study, gel chromatography of infusate and serum 125I-PRL yielded results that have a direct bearing on the interpretation of MCR data for PRL, and possibly for other polypeptide hormones as well. Infusate was almost completely homogeneous, consisting of c90% peak III material. However, within 5 min, peak I and II material had begun to accumulate, and at 180 min the area of peak I was almost as great as the area of peak III. These larger, new forms were products of clearance and should not have been included in the MCR determination of native, infused (peak III) PRL. However, MCR calculations rely on immunoprecipitable hormone. For the reason that 20-30% of all the immunoprecipitable counts were, in fact, peak I iodoprolactin, and because this peak accounted for 30-40% of the total protein counts at equilibrium, the immunoprecipitable counts that were a result purely of peak III were only 80% of that which was calculated. If, on the average, 20% of immunoprecipitable counts were the result of "contamination" with aggregation products, then a revised MCR would have been 20% greater than estimated above.
However, PRL exists as multiple forms in serum, and large species (peaks I and II) may comprise up to 40% of the total circulating immunoactive hormone (45) . Because these forms display parallelism with authentic PRL (peak III) in the PRL radioimmunoassay (48) The molecular nature of the heterogeneous forms of labeled and unlabeled PRL is unclear. In the electrophoretic studies outlined above, we showed that labeled peak I PRL was almost totally converted to immunoactive peak III using denaturing conditions. This suggests that covalent linkages are not involved in the structure of this larger species. Approximately 30% of labeled peak II PRL migrated to the position of peak III using both nonreducing and reducing conditions, in agreement with the recently published data of Garnier et al. (49) . However, the immunoprecipitability of this peak III material was greatly diminished, compared with native peak III. It can be inferred from these data that labeled peak I PRL is a noncovalently bound aggregate species, and although peak II also contains some peak III material, its nature is more complex.
It should be recalled that these studies were performed using peaks of iodoprolactin that were generated during iodination. Although each peak has a great deal of similarity with peaks isolated from serum with respect to molecular weight and immunogenicity, it is possible that the iodination peaks that we studied by electrophoresis represented entirely different molecules than those that arose in vivo.
The large 125I peak seen in the 180-min elution profile ( Fig. 6C) Of great importance is the fact that high molecular weight immunoactive species normally exist in human serum, and, in some pathological states (PRL-secreting tumors), these larger forms may comprise a greater fraction oftotal PRL than in normal subjects (49, 54, 55) . Because of the variability in circulating PRL heterogeneity, the PR that is calculated will not necessarily reflect the PR of the predominant circulating PRL species in any given individual.
It is evident from the preceding discussion that chromatographic analysis of iodinated serum species, with concomitant immunoprecipitation studies, should be an integral part of all MCR determinations performed with iodinated polypeptides. These studies are necessary to determine the extent to which "nonnative" forms of a hormone arise and immunoprecipitate, and the extent to which MCR and PR calculations are affected. In addition, all studies should include data that confirm not only identical disappearance rates for labeled and unlabeled honnones, but also data demonstrating the absence of deiodination of labeled hormone under in vitro conditions. These caveats apply to all hormones that display heterogeneity in serum, and it should be emphasized that MCR and PR data under these circumstances are at best only approximations of in vivo events.
